Abivax SA American Depositary Shares (ABVX)
Stock · NASDAQ · Health Care
$88.1as of 10/16/2026
Price chart
Active signals
ABVX Signal Track Record
How signals performed across all stocks →What ABVX's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 20 | -1.2% | 50% | September 15, 2026 |
| Bollinger Band Breakout | 10 | -4.9% | 40% | June 30, 2026 |
| Bollinger Band Breakdown | 9 | -2.0% | 44% | September 15, 2026 |
| 200-Day Moving Average TouchActive now | 4 | -6.6% | 0% | September 8, 2026 |
| Any 20-session window (baseline) | -1.2% | 48% |
Computed by MarketWall from daily closing prices since August 7, 2024. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About ABVX
ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn's disease. T…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 98
- Website
- www.abivax.com/
Fundamentals
- 1-day range
- $88.14$91.48
- Market cap
- $11.19B
- P/E (trailing)
- —
- P/E (forward)
- -23.17
- EPS (trailing)
- $-5.82
- Dividend yield
- —
- Beta
- 1.01
- Avg. volume
- 1.11M
Forecasts
12 analyst ratings
Abivax SA American Depositary Shares Competitors
Chosen by industry and closest market cap.
- ABVXAbivax SA American Depositary Shares$88.13▼ 4.60%Market cap $11.19BP/E —$60.45$139
- AXSMAxsome Therapeutics Inc. Common Stock$157.14▼ 2.87%Market cap $10.81BP/E —$120.12$260.19
- SMMTSummit Therapeutics Inc. Common Stock$14.63▼ 4.81%Market cap $10.80BP/E —$12.07$29.23
- CORTCorcept Therapeutics Incorporated Common Stock$110.16▼ 2.83%Market cap $11.67BP/E 225.11$28.66$126.38
- MDGLMadrigal Pharmaceuticals Inc. Common Stock$449.74▼ 2.19%Market cap $11.79BP/E —$393.61$615
- BMRNBioMarin Pharmaceutical Inc. Common Stock$54.68▼ 2.44%Market cap $11.88BP/E 151.14$49.26$70.98
- PRAXPraxis Precision Medicines Inc. Common Stock$241.76▼ 2.61%Market cap $10.32BP/E —$50.56$392.7
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| ABVX Abivax SA American Depositary Shares | $11.19B | — | $88.13 | ▼ 4.60% | $60.45$139 |
| AXSM Axsome Therapeutics Inc. Common Stock | $10.81B | — | $157.14 | ▼ 2.87% | $120.12$260.19 |
| SMMT Summit Therapeutics Inc. Common Stock | $10.80B | — | $14.63 | ▼ 4.81% | $12.07$29.23 |
| CORT Corcept Therapeutics Incorporated Common Stock | $11.67B | 225.11 | $110.16 | ▼ 2.83% | $28.66$126.38 |
| MDGL Madrigal Pharmaceuticals Inc. Common Stock | $11.79B | — | $449.74 | ▼ 2.19% | $393.61$615 |
| BMRN BioMarin Pharmaceutical Inc. Common Stock | $11.88B | 151.14 | $54.68 | ▼ 2.44% | $49.26$70.98 |
| PRAX Praxis Precision Medicines Inc. Common Stock | $10.32B | — | $241.76 | ▼ 2.61% | $50.56$392.7 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- ABIVAX (ABVX) Uses More Cash. Can its Funding Cover a Potential Launch?Yahoo · 9/26/2026
- 10 Health Care Stocks With Whale Alerts In Today’s SessionBenzinga · 9/25/2026
- 10 Health Care Stocks Whale Activity In Today’s SessionBenzinga · 9/24/2026
- Abivax: Priced Right Ahead Of 2 Make-Or-Break CatalystsSeekingAlpha · 9/23/2026
- BTIG Reiterates Buy on Abivax, Maintains $175 Price TargetBenzinga · 9/22/2026
- These Analysts Slash Their Forecasts On Abivax Following H1 ResultsBenzinga · 9/22/2026
- Truist Securities Maintains Buy on Abivax, Lowers Price Target to $151Benzinga · 9/22/2026
- Wedbush Maintains Neutral on Abivax, Lowers Price Target to $118Benzinga · 9/22/2026
Institutional Ownership
March 31, 2026
- Total shares held
- 52.15M
- Total value held
- $5.59B
- Institutional holders
- 249
- Unknown6.48M
- Unknown4.55M
- Unknown3.47M
- Unknown1.70M
- Unknown1.50M
- Unknown1.46M
- Unknown1.44M
- Unknown1.34M
- Unknown1.32M
- Unknown1.29M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 4, 2026
Abivax to present seven obefazimod abstracts at UEG Week 2026
Abivax plans to share seven scientific abstracts on its lead candidate, obefazimod, at the upcoming UEG Week 2026 conference. The data focuses on the drug's potential for treating active ulcerative colitis, which is a key milestone for the company's pipeline. While the stock currently trades near its 52-week low, analysts maintain an average price target of $164.00, suggesting a gap between current market sentiment and long-term expectations.
Abivax to present seven obefazimod abstracts at UEG Week 2026. Abivax plans to share seven scientific abstracts on its lead candidate, obefazimod, at the upcoming UEG Week 2026 conference. The data focuses on the drug's potential for treating active ulcerative colitis, which is a key milestone for the company's pipeline. While the stock currently trades near its 52-week low, analysts maintain an average price target of $164.00, suggesting a gap between current market sentiment and long-term expectations.